Our team consists of scientists, engineers, quality assurance specialists, product expertise, global health experts, and clinical and regulatory affairs specialists. We have a CEO, CTO (technology officer), CPDO (product officer), CSDO (strategy and development officer), a Director of Clinical Affairs, and a Lead Scientist. This is our immediate team structure.
Asma Mirza – Asma Mirza is the CEO of Steradian Technologies, Inc, a Houston-based biotech startup that is bridging the gap of healthcare inaccessibility by developing high-tech medical platforms that cost the price of a latte! Asma received her graduate degree in Global Health and Human Rights from Duke University and has led extensive projects globally in the Caribbean, Middle East, and South Asia. Her background in data analytics drives much of the software interface and machine learning that Steradian’s technology incorporates. She was the original founder of Pheramor, Inc., a genetics-tech startup. She served as its CEO before transitioning to Steradian to pursue her passion for medicine, deep-tech, and global health.
John Marino – John Marino is the Chief Product Officer. His role in this project is in research and development for hardware, program management, supplier management, and coordination between device engineering and bioengineering. I design and source hardware components, construct and assemble parts, and manage the materials budget. He also ensures that the device and bio developments move in parallel to ensure the overall solution functions as intended. He has managed many successful commercial products throughout their entire life cycle; from conception to launch/volume production, and finally to end of life and replacement in the market, but have never been more excited about a product than this one.
Jerry Aguren – Jerry Aguren is the CTO for Steradian Technologies with a distinguished 40 years’ experience leading scientific and engineering teams in conducting research and development in diverse areas, such as robotics, software, optics, electronics, and medicine. In particular, as the CTO for Steradian Technologies, he developed the electronics, optics, software, and signal algorithms for the RUMI photonic diagnostic system. This system uses proprietary optics that result in discrete focal point manipulation for rapid amplification and detection of photons. The system’s field-of-view and resolution allow for gathering all emitted photons in one location, as well as indicating when enough sample has been collected. In addition, he has developed the optical and electrical architectures for Steradian Technologies.
Ingrid Stuiver, PhD – Chief of Strategy and Development – In addition to her background in cell & molecular biology and biochemistry, Ingrid has 20 years of extensive experience in cross-functional operations and leading the successful translation of technologies from academia through the development stages in a corporate setting. Previously, as Sr. Director of Translational Research at the La Jolla Institute for Immunology, Ingrid supported the start of 4 spin-outs companies focused on neoantigen vaccines/T Cell receptor therapies for cancer, Anti-atherosclerosis vaccines and pharmaceuticals as well as bispecific antibodies for autoimmune disorders. Technologies licensed to for profit entities involved stabilized structures for use as infectious disease vaccines and research
tools, therapeutic and research antibodies targeting aspects of the Spike and N proteins and peptides associated with T-cell specific SARS-CoV-2 responses. Perhaps most importantly, she brought diagnostic technologies to the institute which resulted in a significant focus on COPD, Cancer as well as a concentrated effort on COVID-19 methods for diagnosis. She has established a SARS-CoV-2 biorepository of blood components and saliva that is still in use today. Technologies on-boarded were saliva-based PCR testing, lateral flow
diagnostics, LAMP assays and optical shadowing. Furthermore, Ingrid cultivates numerous relationships with external research reagent, drug screening, pharma, biotechnology and VC companies to foster interest in translating immunology-based technologies from academia to for profit development pathways.
Tra Tran – Tra Tran is the Director of Business Development and Research Affairs at Steradian Technologies. She is an experienced qualitative researcher with experience in academia, multi-lateral non-governmental organizations, and nonprofits. Tra worked as the Program Director at The Kenan Institute for Ethics at Duke University, directing two human rights and health projects. Tra has a well-established research and quantitative data background with a Master’s of Science (MSc) in Global Health and a Bachelor of Arts (B.A.) focused in Psychology and Cultural Anthropology from Duke University.